Georgia Tech Research Horizons
Spring/Summer 2004
Target and Control Strategies to Battle Cancer
Target & Control Strategies
Mining Breast Cancer Imaging Data
Molecular Complexity
Treating a Chemotherapy Side Effect
Catching Cancer Before It Spreads
Sentinel Against Ovarian Cancer
Peering into the Body - MRI
Changing Cell Signaling Pathways
Molecular Profiles of Cancer
3-D Modeling - Prostate Cancer
Neutron-Based Therapies
Calculating Radiation Dosage
Fighting Disease with Disease
Optimizing Radiation Therapy
A Breast Cancer Survivor’s Story
A Stomach Cancer Survivor’s Story
More Geogia Tech Cancer Research



Cover Story Sidebar
Molecular Complexity

Researcher explores the molecular
events that turn on genes that are
overexpressed in some cancers.

by JANE M. SANDERS

IN BREAST AND OTHER types of cancer, genes that encode the cytochrome P450 family of enzymes are overexpressed, creating an overproduction of these proteins.
photo by Gary Meek

Assistant Professor of Biology Marion Sewer studies the genes that encode a subset of cytochrome P450 enzymes that make steroid hormones such as estrogen. Her research team included recent graduate Houman Khalili, pictured here. (300-dpi JPEG version - 846k)

Under normal conditions, cytochrome P450s perform a variety of functions – from ridding the body of toxic compounds such air pollutants and pharmaceutical drugs to producing essential biological molecules, such as cholesterol and hormones.

Georgia Tech Assistant Professor of Biology Marion Sewer studies the genes that encode a subset of cytochrome P450 enzymes that make steroid hormones such as estrogen, testosterone and cortisol (the “stress” hormone). Sewer primarily investigates the molecular events that turn on these genes in response to chronic stresses.

“This research is complex at the molecular level in terms of the steps involved in turning on genes, given all the proteins and pathways that are involved,” Sewer notes.

But Sewer is now extending this basic research to studies of cancers that are “hormone dependent” – that is, their progression is linked to an overproduction of hormones.
courtesy National Cancer Inst.

In breast cancer, the current treatment is a chemotherapy drug called Taxol (model of a Taxol molecule shown here), which inhibits the ability of estrogen to turn on genes. A more effective treatment in the future may be to combine Taxol with an agent that inhibits estrogen production in the breast only.

For example, estrogen is overproduced in breast cancer, and testosterone is overproduced in prostate cancer. This expanded research program was funded in 2003 with a five-year grant from the Georgia Cancer Coalition.

In breast cancer, the current treatment is a chemotherapy drug called Taxol, which inhibits the ability of estrogen to turn on other genes. A more effective treatment in the future may be to combine Taxol with an agent that inhibits estrogen production in the breast only, Sewer notes. Her research could contribute to the development of such a drug, she adds.

But Sewer must first conduct more basic research on the P450 gene that converts estrogen to a toxic compound that binds to DNA and leads to cancer. This particular gene is overexpressed in more than 95 percent of cancerous breast tissue. Though this gene has a documented role in causing other cancers – including stomach cancer and smoking-related lung cancer – its function is not clearly understood in breast cancer, Sewer says. If her research team can learn why this gene is turned on at such a high level, then they might be able to identify a way to turn it off in the breast.

At this stage in their research, Sewer and her team of six undergraduate and graduate students are characterizing different regions of this gene and how those regions affect expression.

She estimates that it will be at least 15 years before her research would lead to human trials of potential pharmaceutical agent that might be developed from her team’s findings.

For more information, contact Marion Sewer at 404-385-4211 or marion.sewer@biology.gatech.edu.

Contents    Research Horizons    GT Research News    GTRI    Georgia Tech

Send questions and comments regarding these pages to webadmin@edi.gatech.edu
Last updated: July 7, 2004